Astute Medical to get $30 million from CRG to aid commercialization of NephroCheck Check System Astute Medical, Inc. And CRG today announced that Astute lately achieved a milestone beneath the conditions of its existing term mortgage agreement with CRG. Yet another $10 million can be open to Astute upon the accomplishment of certain income milestones. CRG includes a deep knowledge of our market and developed a framework to greatly help us grow our business. Related StoriesUsing integrated molecular pathology to control incidental pancreatic cysts: an interview with Dr Ananya DasRE. This test may be the only biomarker check available to assess threat of AKI. The expense in Astute Medical represents our continuing commitment to offering minimally dilutive funding alternatives to growing businesses with novel items, stated Charles Tate, chairman of CRG.. Continue reading →

Guys with bone disorders or secondary causes of osteoporosis were excluded from the scholarly study. Along with the dietary questionnaire, the males taking part in the analysis experienced their bone mineral density measured at the lumbar spine and four different hip sites based on the guidelines produced by the International Culture for Clinical Densitometry for the analysis of osteoporosis. Our research shows that it does provide a good pointer to whether a prostate cancer tumor patient also has osteoporosis.. Calcium intake could be used seeing that a prognostic factor for osteoporosis Measuring a man's daily calcium intake is an effective way of identifying prostate cancer patients with a higher than average threat of osteoporosis, based on the April issue of the urology journal BJU International. Continue reading →